NASDAQ:ELGX - Endologix Stock Price, Price Target & More

$4.26 +0.03 (+0.71 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$4.23
Today's Range$4.21 - $4.29
52-Week Range$3.75 - $7.66
Volume219,679 shs
Average Volume638,678 shs
Market Capitalization$351.06 million
P/E Ratio-8.88
Dividend YieldN/A
Beta0.32

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Debt-to-Equity Ratio2.77%
Current Ratio2.36%
Quick Ratio1.62%

Price-To-Earnings

Trailing P/E Ratio-8.88
Forward P/E Ratio-5.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.16 million
Price / Sales1.98
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book4.73

Profitability

EPS (Most Recent Fiscal Year)($0.48)
Net Income$-66,400,000.00
Net Margins-36.65%
Return on Equity-44.91%
Return on Assets-10.61%

Miscellaneous

Employees675
Outstanding Shares83,990,000

How to Become a New Pot Stock Millionaire

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix Inc (NASDAQ:ELGX) announced its quarterly earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.13. The medical instruments supplier earned $44 million during the quarter, compared to analyst estimates of $44.91 million. Endologix had a negative return on equity of 44.91% and a negative net margin of 36.65%. The firm's revenue was down 7.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.30) earnings per share. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Endologix.

What price target have analysts set for ELGX?

9 Wall Street analysts have issued 1 year price targets for Endologix's stock. Their predictions range from $4.00 to $7.00. On average, they expect Endologix's stock price to reach $5.3571 in the next year. View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:
  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (3/19/2018)
  • 2. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John McDermott, CEO & Director (Age 58)
  • Mr. Vaseem Mahboob, CFO & Principal Accounting Officer (Age 49)
  • Dr. Michael V. Chobotov Ph.D., Chief Technology Officer (Age 57)
  • Mr. Robert D. Mitchell, Consultant (Age 56)
  • Mr. John Onopchenko, Chief Operating Officer (Age 59)

Has Endologix been receiving favorable news coverage?

Media stories about ELGX stock have been trending somewhat positive recently, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endologix earned a media sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the medical instruments supplier an impact score of 46.01 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $4.26.

How big of a company is Endologix?

Endologix has a market capitalization of $351.06 million and generates $181.16 million in revenue each year. The medical instruments supplier earns $-66,400,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Endologix employs 675 workers across the globe.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (ELGX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  671
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endologix (NASDAQ:ELGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Endologix in the last 12 months. Their average twelve-month price target is $5.3571, suggesting that the stock has a possible upside of 25.75%. The high price target for ELGX is $7.00 and the low price target for ELGX is $4.00. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.3571$5.3571$5.3571$6.3333
Price Target Upside: 25.75% upside22.31% upside0.13% upside10.53% upside

Endologix (NASDAQ:ELGX) Consensus Price Target History

Price Target History for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ:ELGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018OppenheimerSet Price TargetHold$5.00LowView Rating Details
1/2/2018JPMorgan ChaseDowngradeNeutral -> UnderweightHighView Rating Details
12/12/2017Piper JaffrayReiterated RatingOverweight -> OverweightHighView Rating Details
11/8/2017Canaccord GenuityReiterated RatingHold$5.00N/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetHold$6.00 -> $5.50N/AView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Endologix (NASDAQ:ELGX) Earnings History and Estimates Chart

Earnings by Quarter for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ:ELGX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.16)($0.16)($0.16)

Endologix (NASDAQ ELGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.18)N/AView Earnings Details
2/21/2018Q4 2017($0.21)($0.08)$44.91 million$44.00 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.17)($0.11)$47.21 million$45.99 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.18)($0.10)$47.58 million$48.60 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
7/21/2011Q2 2011($0.07)($0.09)ViewN/AView Earnings Details
4/21/2011Q1 2011($0.06)($0.09)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.01)($0.01)ViewN/AView Earnings Details
7/22/2010Q2 2010($0.01)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.01)($0.01)ViewN/AView Earnings Details
7/22/2009Q2 2009($0.02)($0.01)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.03)($0.03)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.06)($0.04)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.07)($0.07)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.06)($0.09)ViewN/AView Earnings Details
4/24/2008Q1 2008($0.07)($0.09)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.08)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Endologix (NASDAQ:ELGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Endologix (NASDAQ ELGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trading History for Endologix (NASDAQ:ELGX)
Insider Trading History for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ ELGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.4668,689View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.0061,380View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00315,699View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00657,608View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.0041,574View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00108,511View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.0041,380View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.8042,594View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00189,269View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.0027,728View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.9544,461View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80663,624View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35158,804View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70318,233View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.0039,243View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.6045,037View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.0088,106View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00569,825View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.8024,825View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00126,080View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00309,890View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.3433,648View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00348,245View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.6050,899View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endologix (NASDAQ ELGX) News Headlines

Source:
DateHeadline
Endovascular Aneurysm Sealing (EVAS) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair (EVAR) in New StudyEndovascular Aneurysm Sealing (EVAS) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair (EVAR) in New Study
finance.yahoo.com - April 25 at 4:53 PM
Endologix (ELGX) to Release Quarterly Earnings on WednesdayEndologix (ELGX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 4:46 AM
$41.27 Million in Sales Expected for Endologix  Inc (ELGX) This Quarter$41.27 Million in Sales Expected for Endologix Inc (ELGX) This Quarter
www.americanbankingnews.com - April 25 at 4:16 AM
-$0.20 EPS Expected for Endologix  Inc (ELGX) This Quarter-$0.20 EPS Expected for Endologix Inc (ELGX) This Quarter
www.americanbankingnews.com - April 23 at 9:08 AM
Royal Bank of Canada Reaffirms "Hold" Rating for Endologix (ELGX)Royal Bank of Canada Reaffirms "Hold" Rating for Endologix (ELGX)
www.americanbankingnews.com - April 15 at 8:37 AM
Endologix (ELGX) Given a $6.00 Price Target at Stifel NicolausEndologix (ELGX) Given a $6.00 Price Target at Stifel Nicolaus
www.americanbankingnews.com - April 13 at 8:18 PM
Has Endologix Inc (NASDAQ:ELGX) Improved Earnings Growth In Recent Times?Has Endologix Inc (NASDAQ:ELGX) Improved Earnings Growth In Recent Times?
finance.yahoo.com - April 11 at 9:40 AM
Endologixs (ELGX) Hold Rating Reiterated at Royal Bank of CanadaEndologix's (ELGX) Hold Rating Reiterated at Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM
$41.33 Million in Sales Expected for Endologix  Inc (ELGX) This Quarter$41.33 Million in Sales Expected for Endologix Inc (ELGX) This Quarter
www.americanbankingnews.com - April 8 at 3:54 AM
Endologix  Inc (ELGX) Expected to Announce Earnings of -$0.20 Per ShareEndologix Inc (ELGX) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 6 at 11:29 AM
Endologix  Inc (ELGX) Receives Consensus Recommendation of "Hold" from AnalystsEndologix Inc (ELGX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 3:24 AM
Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018
finance.yahoo.com - April 3 at 4:48 PM
Royal Bank of Canada Cuts Endologix (ELGX) Price Target to $4.00Royal Bank of Canada Cuts Endologix (ELGX) Price Target to $4.00
www.americanbankingnews.com - April 1 at 11:24 AM
Stifel Nicolaus Trims Endologix (ELGX) Target Price to $5.50Stifel Nicolaus Trims Endologix (ELGX) Target Price to $5.50
www.americanbankingnews.com - April 1 at 9:47 AM
Endologix (ELGX) Cut to "Strong Sell" at ValuEngineEndologix (ELGX) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
Endologix (ELGX) Cut to "Underweight" at JPMorgan ChaseEndologix (ELGX) Cut to "Underweight" at JPMorgan Chase
www.americanbankingnews.com - March 31 at 11:55 AM
Reviewing Endologix (ELGX) & Luminex (LMNX)Reviewing Endologix (ELGX) & Luminex (LMNX)
www.americanbankingnews.com - March 27 at 3:08 AM
Endologix, Inc. (ELGX) Expected to Announce Quarterly Sales of $41.33 MillionEndologix, Inc. (ELGX) Expected to Announce Quarterly Sales of $41.33 Million
www.americanbankingnews.com - March 22 at 4:40 AM
Endologix Gains on Test ResultsEndologix Gains on Test Results
www.baystreet.ca - March 20 at 4:39 PM
-$0.19 Earnings Per Share Expected for Endologix, Inc. (ELGX) This Quarter-$0.19 Earnings Per Share Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - March 20 at 11:29 AM
BRIEF-Endologix Reports Positive Results From Global Encore Analysis With Polymer Endovascular Aneurysm RepairBRIEF-Endologix Reports Positive Results From Global Encore Analysis With Polymer Endovascular Aneurysm Repair
www.reuters.com - March 20 at 9:18 AM
Endologix (ELGX) Rating Increased to Hold at Zacks Investment ResearchEndologix (ELGX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 19 at 10:40 PM
7 Stocks Moving In Mondays After-Hours Session7 Stocks Moving In Monday's After-Hours Session
feeds.benzinga.com - March 19 at 8:19 PM
Endologix (ELGX) Reports Positive Results from Global ENCORE Analysis with Polymer EVAR - StreetInsider.comEndologix (ELGX) Reports Positive Results from Global ENCORE Analysis with Polymer EVAR - StreetInsider.com
www.streetinsider.com - March 19 at 4:40 PM
Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair ... - Business Wire (press release)Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair ... - Business Wire (press release)
www.businesswire.com - March 19 at 4:40 PM
Will Endologix Inc’s (NASDAQ:ELGX) Earnings Grow In The Year Ahead?Will Endologix Inc’s (NASDAQ:ELGX) Earnings Grow In The Year Ahead?
finance.yahoo.com - March 19 at 4:40 PM
Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft SystemsEndologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems
finance.yahoo.com - March 19 at 4:40 PM
Endologix, Inc. (ELGX) Given Average Rating of "Hold" by BrokeragesEndologix, Inc. (ELGX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 4:47 AM
Endologix (ELGX) Reports Enrollment of 1st Patient in EVAS2 IDE Clinical Study - StreetInsider.comEndologix (ELGX) Reports Enrollment of 1st Patient in EVAS2 IDE Clinical Study - StreetInsider.com
www.streetinsider.com - March 7 at 5:38 PM
Endologix, Inc. (ELGX) Holdings Boosted by Senzar Asset Management LLCEndologix, Inc. (ELGX) Holdings Boosted by Senzar Asset Management LLC
www.americanbankingnews.com - March 5 at 3:45 PM
655,815 Shares in Endologix, Inc. (ELGX) Purchased by Prosight Management LP655,815 Shares in Endologix, Inc. (ELGX) Purchased by Prosight Management LP
www.americanbankingnews.com - March 5 at 2:54 PM
Free Research Report as Haemonetics’ Revenues Grew 2.7% and Adjusted EPS Surged 44%Free Research Report as Haemonetics’ Revenues Grew 2.7% and Adjusted EPS Surged 44%
finance.yahoo.com - March 5 at 9:11 AM
Endologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing SystemEndologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing System
finance.yahoo.com - March 5 at 9:11 AM
Zacks: Brokerages Anticipate Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $41.33 MillionZacks: Brokerages Anticipate Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $41.33 Million
www.americanbankingnews.com - March 5 at 8:18 AM
Endologix (ELGX) Downgraded by ValuEngineEndologix (ELGX) Downgraded by ValuEngine
www.americanbankingnews.com - March 4 at 7:16 PM
Endologix, Inc. (ELGX) Expected to Announce Earnings of -$0.19 Per ShareEndologix, Inc. (ELGX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - March 3 at 9:56 AM
Endologix, Inc. (ELGX) Shares Sold by Lombard Odier Asset Management USA CorpEndologix, Inc. (ELGX) Shares Sold by Lombard Odier Asset Management USA Corp
www.americanbankingnews.com - March 2 at 6:16 PM
Endologix, Inc. (ELGX) Holdings Lessened by Cortina Asset Management LLCEndologix, Inc. (ELGX) Holdings Lessened by Cortina Asset Management LLC
www.americanbankingnews.com - March 2 at 12:48 PM
What You Must Know About Endologix Inc’s (NASDAQ:ELGX) Financial StrengthWhat You Must Know About Endologix Inc’s (NASDAQ:ELGX) Financial Strength
finance.yahoo.com - February 28 at 5:20 PM
Endologix (ELGX) Given a $5.00 Price Target by Oppenheimer AnalystsEndologix (ELGX) Given a $5.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - February 22 at 5:02 PM
John McDermott Steps Down as Endologix (ELGX) CEOJohn McDermott Steps Down as Endologix (ELGX) CEO
www.streetinsider.com - February 22 at 8:59 AM
Endologix reports 4Q lossEndologix reports 4Q loss
finance.yahoo.com - February 22 at 8:59 AM
Endologix (ELGX) Issues  Earnings ResultsEndologix (ELGX) Issues Earnings Results
www.americanbankingnews.com - February 21 at 9:30 PM
Endologix Q4 Earnings PreviewEndologix Q4 Earnings Preview
finance.yahoo.com - February 21 at 4:56 PM
Zacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.20 MillionZacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.20 Million
www.americanbankingnews.com - February 16 at 4:06 AM
-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - February 14 at 3:10 PM
Endologix (ELGX) Set to Announce Quarterly Earnings on TuesdayEndologix (ELGX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 13 at 2:56 AM
Endologix, Inc. (ELGX) Receives Consensus Recommendation of "Hold" from BrokeragesEndologix, Inc. (ELGX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 1:22 AM
Endologix (ELGX) Upgraded at BidaskClubEndologix (ELGX) Upgraded at BidaskClub
www.americanbankingnews.com - February 10 at 12:14 PM
Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Endologix, Glaukos, and Mazor RoboticsQuotidian Technical Highlights on Selected Medical Supplies Stocks -- Endologix, Glaukos, and Mazor Robotics
www.prnewswire.com - February 7 at 6:34 AM

SEC Filings

Endologix (NASDAQ:ELGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endologix (NASDAQ:ELGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endologix (NASDAQ ELGX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.